Shaily Engineering Plastics Reports Robust Q2 FY26 Results with 34% Revenue Growth
Shaily Engineering Plastics Limited (SEPL) reported robust Q2 FY26 results with revenue up 34% to INR 257.00 crores. EBITDA doubled to INR 82.00 crores, and PAT surged 134% to INR 51.00 crores. The healthcare segment grew 163% YoY, now contributing 38% to overall revenue. SEPL launched a new GLP-1 device, signed new projects, and is expanding pen manufacturing capacity. The company processed 6,652 tons of polymers, a 7.5% increase from Q2 FY25. Exports accounted for 68% of total revenue. SEPL is investing INR 125.00 crores for capacity expansion in FY26 and expects the healthcare segment to grow 30-40% annually in the coming years.
*this image is generated using AI for illustrative purposes only.
Shaily Engineering Plastics Limited (SEPL) has reported strong financial results for the second quarter of fiscal year 2026, demonstrating significant growth and expansion in its healthcare segment. The company's strategic focus on innovative drug delivery devices, particularly for GLP-1 medications, has driven its performance.
Financial Highlights
- Revenue grew by 34% year-on-year to INR 257.00 crores in Q2 FY26
- EBITDA doubled to INR 82.00 crores, with margins expanding by 1,030 basis points to 31.80%
- Profit After Tax (PAT) increased by 134% to INR 51.00 crores, with margins improving by 860 basis points to 20.00%
Segment Performance
| Segment | Q2 FY26 Revenue (INR Crores) | YoY Growth |
|---|---|---|
| Healthcare | 98.60 | 163% |
| Consumer | 135.00 | -3% |
| Industrial | 23.00 | 45% |
The healthcare segment has shown remarkable growth, now contributing 38% to the overall revenue mix, doubling from the previous year.
Operational Highlights
- SEPL processed 6,652 tons of polymers in Q2 FY26, a 7.5% increase from Q2 FY25
- Machine utilization rate stands at 48% in both Q2 and H1 FY26
- Exports accounted for 68% of total revenue in Q2 FY26
Strategic Developments
Healthcare Segment Expansion
- Launched next-generation GLP-1 device, Shaily Axiom Max
- Signed four new projects across GLP-1 and other therapies
- Installed 19 new machines at manufacturing facilities
Capacity Expansion
- Increasing pen manufacturing capacity from 40 million to 80 million units by end of FY26
- Investing approximately INR 125.00 crores for capacity expansion in FY26
Consumer Segment
- Awarded 5 new projects from 3 marquee home furnishings customers
Industrial Segment
- Secured 1 new project from an automotive major
Consumer Electronics
- Expected to begin revenue generation in H2 FY26
Future Outlook
- Healthcare segment projected to grow at over 30-40% annually for the next few years
- Exploring opportunities in semiconductor business
- Potential for significant growth in Consumer Electronics segment by FY28
Amit Sanghvi, Managing Director of SEPL, commented on the results: "We have delivered strong revenue growth of 34% to INR 257.00 crores on a year-on-year basis, with EBITDA margins expanding by over 1,000 basis points to 31.80%. The growth is attributable to improved traction in our Healthcare segment, which showed a growth of 163% on a year-on-year basis to INR 98.60 crores."
The company's focus on innovation and expansion in the healthcare segment, particularly in drug delivery devices for GLP-1 medications, positions it well for continued growth. With ongoing capacity expansion and new product developments, Shaily Engineering Plastics appears poised for sustained performance in the coming years.
Investors should note that while the company's growth trajectory is impressive, market conditions and regulatory approvals, especially in international markets like Canada, may impact future performance. The management remains optimistic about the company's prospects across its diverse business segments.
Historical Stock Returns for Shaily Engineering Plastics
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +6.18% | +12.69% | +16.62% | +67.21% | +154.73% | +589.87% |
15
